Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers

NCT02423590 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT02423590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02423590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2014
Completion date
June 30, 2018
Enrollment
140 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell lung cancer